Smoking Cessation in the Cardiac Patient
Publisher
Springer London
Reference24 articles.
1. Kannel WB, Dagostino RB, Belanger AJ. Fibrinogen, cigarette-smoking, and risk of cardiovascular diseases—insights from the Framingham study. Am Heart J 1987; 113:1006–1010.
2. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease, an update. J Am Coll Cardiol 2004;43:1731–1737.
3. Mueller HS, Cohen LS, Braunwald E, et al. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI) trial, phase II. Circulation 1992;85:1254–1264.
4. Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol 1997;29:1422–1431.
5. Barbash GI, Reiner J, White HD, et al. Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the “smoker's paradox” from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1995;26:1222–1229.